Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACES: Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers
NCT01349881Phase 3Active, not recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Aug 2013
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eflornithine and sulindac in colorectal neoplasm (4 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Event rate of high-risk adenoma or second primary colorectal cancer at 3 years. Started Aug 2013; status: active, not recruiting.
02
Drugs
eflornithinesulindac
03
Conditions
colorectal neoplasm
Beyond the preview
Go deeper on NCT01349881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349881.